Pressmeddelanden från Zealand Pharma

Start Nyheter Forum Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 13 okt 22:30

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases 07 okt 19:14

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes 05 okt 18:30

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)01 okt 15:30

Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts 01 okt 09:30

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes 30 sep 22:00

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 30 sep 00:03

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology 28 sep 17:00

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)22 sep 17:00

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity 21 sep 17:00

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)18 sep 12:10

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome 14 sep 17:00

Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)10 sep 17:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 09 sep 17:00

Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference 07 sep 17:00

Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)02 sep 17:00

Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)31 aug 17:00

Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)28 aug 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 24 aug 17:05

Zealand Pharma – Notification of holding of treasury shares 24 aug 17:00

Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)17 aug 17:00

Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)13 aug 07:00

Zealand Pharma Announces Financial Results for the First Half of 2026 12 aug 22:05

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide 10 aug 17:00

Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)06 aug 17:00

Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results 03 aug 17:00

Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)27 jul 17:00

Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)20 jul 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 20 jul 17:00

Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)13 jul 17:00

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)06 jul 17:00

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)30 jun 22:01

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 30 jun 22:00

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.29 jun 17:00

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)22 jun 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 22 jun 17:00

Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)15 jun 17:00

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)10 jun 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 08 jun 17:05

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)08 jun 17:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 07 jun 20:30

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis 05 jun 22:45

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity 02 jun 17:00

Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference 01 jun 17:00

Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)29 maj 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 27 maj 17:00

Zealand Pharma to participate in the Jefferies Global Healthcare Conference 27 maj 09:00

Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions 26 maj 17:30

Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)26 maj 16:00

Resolutions from Zealand Pharma's Extraordinary General Meeting 2026 14 maj 17:00

Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)07 maj 07:05

Zealand Pharma - Execution framework for share buy-back program 07 maj 07:00

Zealand Pharma Announces Financial Results for the First Three Months of 2026 07 maj 06:55

Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program 01 maj 15:01

The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting 01 maj 15:00

Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026 30 apr 17:01

Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results 29 apr 19:01

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management 28 apr 08:00

Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial 22 apr 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 19 apr 22:05

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 19 apr 22:00

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 14 apr 16:00

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations 31 mar 22:00

Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 26 mar 16:57

Resolutions from Zealand Pharma's Annual General Meeting 2026 24 mar 15:00

Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation 19 mar 22:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 09 mar 17:01

Zealand Pharma to participate in upcoming investor conferences in March 2026 05 mar 19:45

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity 19 feb 14:00

Zealand Pharma convenes its Annual General Meeting 2026 19 feb 07:00

Zealand Pharma Announces Financial Results for the Full Year 2025 18 feb 07:30

Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 12 feb 17:01

Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results 09 jan 08:00

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy 05 jan 17:05

Zealand Pharma to present at the J.P. Morgan Healthcare Conference 31 dec 2025 17:05

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 19 dec 2025 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 11 dec 2025 22:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 11 dec 2025 07:05

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health 11 dec 2025 07:00

Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases 05 dec 2025 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 01 dec 2025 17:00

REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 12 nov 2025 17:30

Zealand Pharma to participate in the Jefferies Global Healthcare Conference 06 nov 2025 17:30

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results 17 okt 2025 17:05

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.30 sep 2025 17:05

Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 24 sep 2025 17:00

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations 11 sep 2025 22:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 11 sep 2025 17:00

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 28 aug 2025 17:00

Zealand Pharma to participate in upcoming investor conferences in September 2025 20 aug 2025 22:00

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.14 aug 2025 07:00

Zealand Pharma Announces Financial Results for the First Half of 2025 07 aug 2025 17:30

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results 18 jul 2025 18:30

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.30 jun 2025 17:05

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 18 jun 2025 17:29

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide 06 jun 2025 22:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 27 maj 2025 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 19 maj 2025 15:00

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer 12 maj 2025 07:00

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025